Based on clinical settings, these results further consolidate the therapeutic rationale targeting KDM6 enzymes in CRC and also pinpoint KDM6B as a potential predictor for recurrence of CRC and other common cancers. The gene discussed is KDM6B; the disease is colorectal carcinoma.